Reference Guide for Integrating Continuous Glucose Monitoring Into Clinical Practice

Abstract

Purpose

Large randomized trials have demonstrated the efficacy of continuous glucose monitoring (CGM) in persons with type 1 diabetes and insulin-treated type 2 diabetes. The purpose of this article is to provide basic knowledge about CGM technology, discuss the use of CGM data in clinical practice, and direct clinicians to online resources that provide comprehensive information and tools relevant to patient selection, education/training, and reimbursement.

Conclusions

Effective use of CGM requires all members of the health care team to become knowledgeable and skilled in integrating CGM into their practices and in teaching their patients how to safely incorporate CGM use into their daily diabetes self-management.

Get full access to this article

View all access options for this article.

References

American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(suppl 1):S55-S64.

Fonseca

Grunberger

Anhalt

et al . Continuous glucose monitoring: a consensus conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract. 2016;22(8):1008-1021.

Dexcom, Inc. Dexcom G6 Continuous Glucose Monitoring Systems User Guide. San Diego, CA: Dexcom, Inc. https://s3-us-west-2.amazonaws.com/dexcompdf/G6-CGM-Users-Guide.pdf. Accessed May 4, 2018.

Dexcom, Inc. Dexcom G5 Mobile Safety Information. https://www.dexcom.com/safety-information#dexcom-g5-mobile-safety-statement. Accessed January 28, 2018.

US Food and Drug Administration. MiniMed 670G System. Summary of Safety and Effectiveness Data (SSED). https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160017b.pdf. Accessed January 21, 2018.

Christiansen

Klaff

Brazg

et al . A prospective multicenter evaluation of the accuracy of a novel implanted continuous glucose sensor: PRECISE II. Diabetes Technol Ther. 2018;20(3):197-206.

US Food and Drug Administration. FreeStyle Libre Flash Glucose Monitoring System. Summary of Safety and Effectiveness Data (SSED). https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160030S017B.pdf. Accessed August 8, 2018.

Beck

Riddlesworth

Ruedy

et al . Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317(4):371-378.

Beck

Riddlesworth

Ruedy

et al . Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167(6):365-374.

10.

Šoupal

Petruželková

Flekač

et al . Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538.

11.

DeSalvo

Miller

Hermann

et al . Continuous glucose monitoring (CGM) and glycemic control among youth with type 1 diabetes (type 1 diabetes): international comparison from the type 1 diabetes exchange and DPV initiative [published online June 20, 2018]. Pediatr Diabetes. doi:10.1111/pedi.12711

12.

Heinemann

Freckmann

Ehrmann

et al . Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391(10128):1367-1377.

13.

van Beers

DeVries

Kleijer

et al . Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11): 893-902.

14.

Polonsky

Fisher

Hessler

. The impact of non-severe hypoglycemia on quality of life in patients with type 2 diabetes. J Diabetes Complications. 2018;32(4):373-378.

15.

Bolinder

Antuna

Geelhoed-Duijvestijn

Kröger

Weitgasser

. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263.

16.

Haak

Hanaire

Ajjan

Hermanns

Riveline

Rayman

. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55-73.

17.

Reddy

Jugnee

El Laboudi

Spanudakis

Anantharaja

Oliver

. A randomised controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med. 2018;35(4):483-490.

18.

Feig

Donovan

Corcoy

et al . Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390:2347-2359.

19.

US Food and Drug Administration. Paradigm REAL-Time Revel System. Summary of Safety and Effectiveness Data (SSED). https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150019b.pdf. Accessed January 21, 2018.

20.

Shivers

Mackowiak

Anhalt

Zisser

. “Turn it off!”: diabetes device alarm fatigue considerations for the present and the future. J Diabetes Sci Technol. 2013;7(3):789-794.

21.

Adolfsson

Parkin

Thomas

Krinelke

. Selecting the appropriate continuous glucose monitoring system—a practical approach. Eur Endocrinol. 2018;14(1):24-29.

22.

Lind

Polonsky

Hirsch

et al . Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317(4):379-387.

23.

Pettus

Edelman

. Use of glucose rate of change arrows to adjust insulin therapy among individuals with type 1 diabetes who use continuous glucose monitoring. Diabetes Technol Ther. 2016;18(suppl 2):S234-S242.

24.

Pettus

Edelman

. Differences in use of glucose rate of change (ROC) arrows to adjust insulin therapy among individuals with type 1 and type 2 diabetes who use continuous glucose monitoring (CGM). Diabetes Technol Ther. 2016;10(5):1087-1093.

25.

Pettus

Edelman

. Recommendations for using real-time continuous glucose monitoring (rtCGM) data for insulin adjustments in type 1 diabetes. J Diabetes Sci Technol. 2017;11(1):138-147.

26.

Aleppo

Laffel

Ahmann

et al . A practical approach to using trend arrows on the Dexcom G5 CGM system for the management of adults with diabetes. J Endocr Soc. 2017;1(12):1445-1460.

27.

Laffel

Aleppo

Buckingham

et al . A practical approach to using trend arrows on the Dexcom G5 CGM system to manage children and adolescents with diabetes. J Endocr Soc. 2017;1(12):1461-1476.

28.

Kudva

Ahmann

Bergenstal

et al . Approach to using trend arrows in the FreeStyle Libre Flash glucose monitoring system in adults [published online November 14, 2018]. J Endocr Soc. doi:10.1210/js.2018-00294

29.

Davis

Wylie-Rosett

. Death to carbohydrate counting? Diabetes Care. 2008;31(7):1467-1468.

30.

Kalergis

Pacaud

Strychar

Meltzer

Jones

Yale

. Optimizing insulin delivery: assessment of three strategies in intensive diabetes management. Diabetes Obes Metab. 2000;2(5):299-305.

31.

Bergenstal

Ahmann

Bailey

et al . Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther. 2013;15(3):198-211.

32.

International Diabetes Center. AGP—Ambulatory Glucose Profile. http://www.agpreport.org/agp/agpreports Accessed September 12, 2018.

33.

Danne

Nimri

Battelino

et al . International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631-1640.

34.

Bergenstal

. Understanding continuous glucose monitoring data. In: Hirsch

Battelino

Peters

Chamberlain

Aleppo

Bergenstal

eds. Role of Continuous Glucose Monitoring in Diabetes Treatment. Arlington, VA: American Diabetes Association; 2018:20-23. https://professional.diabetes.org/sites/professional.diabetes.org/files/media/final_ada-abbott_cgm_compendium_final.pdf. Accessed September 12, 2018.

35.

Bergenstal

Beck

et al . Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275-2280.

36.

Medtronic. Guardian Connect System User Guide. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/GuardianT%20Connect%20CGM%20System%20User%20Guide.PDF. Accessed August 12, 2018.

37.

Senseonics. Eversense CGM Safety Information. https://www.eversensediabetes.com/safety-info/. Accessed August 12, 2018.

38.

Abbott Diabetes Care. FreeStyle Libre Indications and Important Safety Information. https://www.myfreestyle.com/provider/safety-information. Accessed August 12, 2018.

39.

Graham

. Continuous glucose monitoring and global reimbursement: an update. Diabetes Technol Ther. 2017;19(suppl 3):S60-S66.

40.

American Medical Association. CPT 2018 Professional. Chicago, IL: American Medical Association, 2017.

41.

Billings

Parkin

Price

. Baseline A1C values predict the magnitude of glycemic improvement in patients with type 1 and type 2 diabetes: subgroup analyses from the diamond study program. Diabetes Technol Ther. 2018;20(8):561-565.